Demographic and clinical characteristics of patients and ADRB2 genotype distribution_
| Age in years (mean±SD) | 11.9±2.7 |
|---|---|
| Gender (%) | M: 59.3; |
| FEV1 before salbutamol (%) (mean±SD) | 87.1±11.3 |
| FEV1 after salbutamol (%) (mean±SD) | 98.8±9.1 |
| Asthma severity: n (%) | |
| Atopic dermatitis: n (%) | 43 (79.6) |
| Serum IgE (IU/mL) (mean±SD) | 143.3±49.5 |
| Blood eosinophils (%) (mean±SD) | 6.3±2.1 |
| Allele +46A>G: n (%) | |
| Allele +79C>G: n (%) | |
| Genotype +46A>G: n (%) | |
| Genotype +79C>G: n (%) |
Comparison of response to salbutamol, severity of the disease and clinical characteristics between carriers of different ADRB2 genotypes_
| +46A>G | AA | GA | GG | p Value |
|---|---|---|---|---|
| dFEV1 (%) (mean±SD) | 9.4±6.2 | 10.4±5.8 | 14.4±6.1 | 0.044 |
| Asthma severity: n (%) | ||||
| mild | 1 (4.3) | 10 (43.5) | 12 (52.2) | |
| moderate | 8 (57.2) | 3 (21.4) | 3 (21.4) | 0.010 |
| severe | 4 (27.9) | 6 (35.3) | 7 (41.2) | |
| Atopic dermatitis: n (%) | 12 (27.9) | 13 (30.2) | 18 (41.9) | 0.244 |
| Eosinophils in peripheral blood (%) (mean±SD) | 6.0±2.5 | 6.3±1.7 | 6.4±2.3 | 0.600 |
| Serum IgE (IU/mL) (mean±SD) | 152.4±47.5 | 128.0±53.3 | 148.9±49.9 | 0.440 |